Frontiers in pediatrics · 2026
Pediatric oral antihypertensive agents: analysis of prescription patterns and patient characteristics in a real-world study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cheng Haixin, Cui Ying, Ma Ziyin, Wang Siyuan, Zhong Xuli, Zhang Jianmin
Аннотация
OBJECTIVES: The aim of this study was to assess prescribing intensity and rational dosing of antihypertensives in children using Defined Daily Dose (DDD) and Drug Utilization Index (DUI).
METHODS: A retrospective cross-sectional analysis was conducted on all antihypertensive prescriptions dispensed at a tertiary children's hospital from May 2023 to April 2024, excluding those with incomplete data or on fixed-dose combinations. Prescription medicine use is basically reasonable when DUI is close to 1 (0.9-1.1), a DUI >1.1 suggests that the actual daily dose exceeds DDD, while a DUI <0.9 indicates underdosing. Statistical analysis was performed using SPSS 23.0 with significance at p < 0.05.
RESULTS: A total of 1,562 prescriptions for 422 children (12-18 years; 76.30% male) were analysed; prevalence peaked at 13 years. Among over-12-year-olds, DUI <0.9 for β-blockers, spironolactone and nifedipine; DUI ≈ 1 for furosemide, captopril and losartan; DUI >1.1 for hydrochlorothiazide, amlodipine, ramipril and fosinopril. Amlodipine comprised 42.8% of total DDDs, followed by fosinopril (25.6%) and ramipril (20.0%). Males showed borderline higher DUI values.
CONCLUSIONS: Hypertension was most prevalent among 13- to 14-year-old, who also exhibited the highest antihypertensive exposure and drug-use intensity relative to girls. Once-daily formulations accounted for the majority of prescriptions. Pediatric oral hypertension dosing remains inconsistent in clinical practice. These findings support sex-specific management and guideline updates to improve blood pressure control in high-risk adolescents.
METHODS: A retrospective cross-sectional analysis was conducted on all antihypertensive prescriptions dispensed at a tertiary children's hospital from May 2023 to April 2024, excluding those with incomplete data or on fixed-dose combinations. Prescription medicine use is basically reasonable when DUI is close to 1 (0.9-1.1), a DUI >1.1 suggests that the actual daily dose exceeds DDD, while a DUI <0.9 indicates underdosing. Statistical analysis was performed using SPSS 23.0 with significance at p < 0.05.
RESULTS: A total of 1,562 prescriptions for 422 children (12-18 years; 76.30% male) were analysed; prevalence peaked at 13 years. Among over-12-year-olds, DUI <0.9 for β-blockers, spironolactone and nifedipine; DUI ≈ 1 for furosemide, captopril and losartan; DUI >1.1 for hydrochlorothiazide, amlodipine, ramipril and fosinopril. Amlodipine comprised 42.8% of total DDDs, followed by fosinopril (25.6%) and ramipril (20.0%). Males showed borderline higher DUI values.
CONCLUSIONS: Hypertension was most prevalent among 13- to 14-year-old, who also exhibited the highest antihypertensive exposure and drug-use intensity relative to girls. Once-daily formulations accounted for the majority of prescriptions. Pediatric oral hypertension dosing remains inconsistent in clinical practice. These findings support sex-specific management and guideline updates to improve blood pressure control in high-risk adolescents.